Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. Two landmark trials published in 2007 and 2012 showed efficacy for adjuvant mitotane in resectable ACC and etoposide/doxorubicin/cisplatin plus mitotane for unresectable ACC, respectively. In this study, we used the National Cancer Database to examine whether treatment patterns and outcomes changed after these trials. The National Cancer Database was used to examine treatment patterns and survival in patients diagnosed with ACC from 2006 to 2015. Treatment modalities were compared within that group and with a historical cohort (1985 to 2005). χ2 tests were performed, and Cox proportional hazards models were created. From 2006 to 2015, 2752 patients were included; 38% of patients (1042) underwent surgery alone, and 31% (859) underwent surgery with adjuvant therapy. Overall 5-year survival rates for all stages after resection were 43% (median, 41 months) in the contemporary cohort and 39% (median, 32 months) in the historical cohort. After 2007, patients who underwent surgery were more likely to receive adjuvant chemotherapy (P = 0.005), and 5-year survival with adjuvant chemotherapy improved (41% vs 25%; P = 0.02). However, survival did not improve in p...Continue Reading
References
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T S KhanB Eriksson
Sep 26, 2001·Cancer·R Vassilopoulou-Sellin, P N Schultz
May 9, 2006·World Journal of Surgery·Electron KebebewAlex McMillan
Aug 10, 2006·The Journal of Clinical Endocrinology and Metabolism·Martin FassnachtBruno Allolio
Jun 8, 2007·The New England Journal of Medicine·Massimo TerzoloAlfredo Berruti
Sep 21, 2007·The New England Journal of Medicine·Jérôme BertheratXavier Bertagna
Mar 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Marcus QuinklerMartin Fassnacht
Nov 1, 2008·Cancer·Karl Y BilimoriaCord Sturgeon
Jun 6, 2009·The Journal of Clinical Endocrinology and Metabolism·Sherita H GoldenPaul W Ladenson
Oct 24, 2009·Annals of Surgical Oncology·Elizabeth G GrubbsJeffrey E Lee
Nov 12, 2009·European Journal of Endocrinology·Sebastian WortmannMartin Fassnacht
Dec 23, 2011·European Journal of Endocrinology·Alfredo BerrutiMassimo Terzolo
May 4, 2012·The New England Journal of Medicine·Martin FassnachtUNKNOWN FIRM-ACT Study Group
Jul 28, 2012·The Journal of Clinical Endocrinology and Metabolism·Matthias KroissMartin Fassnacht
Jan 16, 2014·The Journal of Clinical Endocrinology and Metabolism·Ciara O'SullivanTito Fojo
Dec 31, 2015·Biomarkers in Cancer·Sherri Z MillisMichael J Demeure
Apr 5, 2018·JAMA Surgery·Ryan P MerkowKarl Y Bilimoria
Jul 26, 2018·European Journal of Endocrinology·Martin FassnachtMassimo Terzolo
Oct 10, 2018·European Journal of Endocrinology·Martin FassnachtMassimo Terzolo
Citations
Jul 7, 2020·ANZ Journal of Surgery·David LeongDean Lisewski
Mar 13, 2021·Current Opinion in Endocrinology, Diabetes, and Obesity·Darko KastelanTina Dusek
May 1, 2021·Journal of Personalized Medicine·Vittoria BasileMassimo Terzolo
Nov 11, 2020·American Journal of Surgery·Ali Al AsadiAdam S Kabaker